MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 2,726 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,206 shares of the company's stock after selling 2,726 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Neurocrine Biosciences were worth $1,259,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in NBIX. UMB Bank n.a. grew its stake in shares of Neurocrine Biosciences by 211.6% in the 4th quarter. UMB Bank n.a. now owns 455 shares of the company's stock worth $62,000 after acquiring an additional 309 shares in the last quarter. Ballentine Partners LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth $229,000. Daymark Wealth Partners LLC bought a new position in Neurocrine Biosciences during the fourth quarter valued at about $244,000. Janney Montgomery Scott LLC increased its holdings in Neurocrine Biosciences by 7.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 17,545 shares of the company's stock worth $2,395,000 after buying an additional 1,150 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in Neurocrine Biosciences by 2.1% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,133 shares of the company's stock worth $1,110,000 after buying an additional 169 shares during the last quarter. Institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Trading Up 1.8%

Shares of Neurocrine Biosciences stock traded up $2.23 on Thursday, reaching $125.26. The stock had a trading volume of 249,366 shares, compared to its average volume of 1,448,724. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $157.98. The company has a market cap of $12.40 billion, a P/E ratio of 38.12, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26. The business's 50 day moving average is $108.81 and its two-hundred day moving average is $121.84.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The company had revenue of $572.60 million during the quarter, compared to analysts' expectations of $587.06 million. Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the business earned $1.20 earnings per share. On average, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences declared that its Board of Directors has initiated a stock repurchase program on Friday, February 21st that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to reacquire up to 4.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its shares are undervalued.

Insider Activity at Neurocrine Biosciences

In related news, Director William H. Rastetter sold 30,000 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $110.20, for a total value of $3,306,000.00. Following the sale, the director now directly owns 37,491 shares of the company's stock, valued at $4,131,508.20. This trade represents a 44.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NBIX. BMO Capital Markets raised their price objective on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. boosted their target price on Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a research note on Wednesday, March 26th. Evercore ISI cut their price target on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Needham & Company LLC lifted their price objective on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Finally, Wall Street Zen downgraded shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Three analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $162.00.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.